ClinicalTrials.gg

Dysmenorrhea clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 432 studies for Dysmenorrhea across more than 10 countries. 109 are recruiting or about to start. 344 of them are mainly about Dysmenorrhea (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
243
Recruiting
59
Status unknown
47
Not yet recruiting
45
Active, not recruiting
16
Terminated
11

Phase

Phase 3
51
Phase 2
37
Phase 4
23
Phase 1
13
Early Phase 1
6

Where

Turkey
81
United States
68
Egypt
37
Pakistan
28
Spain
23
China
21

Who develops what

Add Dysmenorrhea to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 4 companies, 2 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Dexa Medica Group and Laboratorios Silanes S.A. de C.V. here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
dexketoprofenRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07901894 · Laboratorios Silanes S.A. de C.V. · Phase 3 · comparator · “Dexketoprofen (Stadium®, Menarini Manufacturing Logistics and Services S.R.L. Conditioned by Grimann, S.A. de C.V. Distributed by: Sanfer Laboratories S.A. de C.V.)” · registered Oct 2026
Menarini Group75% of its industry studies11 study
EstradiolEarlier only
Evidence
  • NCT04372121 · Kissei Pharmaceutical Co., Ltd. · Phase 3 · background · “Add-back capsule (E2 1 mg / NETA 0.5 mg)” · registered Apr 2020
  • NCT04335591 · Kissei Pharmaceutical Co., Ltd. · Phase 3 · background · “Add-back capsule (E2 1 mg / NETA 0.5 mg)” · registered Apr 2020
  • NCT03992846 · Kissei Pharmaceutical Co., Ltd. · Phase 3 · background · “Add-back capsule (E2 1 mg / NETA 0.5 mg)” · registered Jun 2019
  • NCT03986944 · Kissei Pharmaceutical Co., Ltd. · Phase 3 · background · “Add-back capsule (E2 1 mg / NETA 0.5 mg)” · registered Jun 2019
  • NCT03654274 · Sumitomo Pharma Co., Ltd. · Phase 3 · background · “Estradiol/norethindrone acetate” · registered Aug 2018
Novo Nordisk A/S17% of its industry studiesUS: off-patent, 37 generics marketed00 studies
IbuprofenEarlier only
Evidence
  • NCT02668822 · Organon & Co. · Phase 3 · background · “Ibuprofen” · registered Jan 2016
  • NCT02668783 · Organon & Co. · Phase 3 · background · “Ibuprofen” · registered Jan 2016
  • NCT01670656 · Organon & Co. · Phase 2 · background · “Ibuprofen” · registered Aug 2012
  • NCT00292747 · Sanofi · Phase 4 · comparator · “Ibuprofen” · registered Feb 2006
Pfizer13% of its industry studiesUS: off-patent, 81 generics marketedEU: off-patent, 1 generic authorized00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.DLBS1442 · Dexa Medica Group · Phase 3 main aimNCT07937462 The Efficacy and Safety of DLBS1442 in Patients With Primary Dysmenorrhea — primary endpoint: Change From Baseline in Visual Analogue Scale (VAS) Pain Score Within 6 Hours After the First Dose · 210 enrolled
  • Jun 2027 est.vipoglanstat · Gesynta Pharma AB · Phase 2 registry mapping onlyNCT07260669 A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis — primary endpoint: Percentage of Participants who meet the Predefined NMPP Responder Criteria from Baseline to Fourth Month of Treatment · 213 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Dysmenorrhea studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here NSAIDs 1 open · Hormonal contraceptives 1 open · COX-2 inhibitors 5 · Estrogens 4

Coming up

31studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger. 11 (19%) take children under 18. 58 (98%) are for women only and 0 (0%) for men only; 20 (34%) take healthy volunteers.

Recruiting studies that take each age, of 59
AgeWomenMen
102 (3%)0 (0%)
1850 (85%)1 (2%)
3040 (68%)1 (2%)
4027 (46%)1 (2%)
5016 (27%)1 (2%)
659 (15%)1 (2%)
758 (14%)1 (2%)
858 (14%)1 (2%)

Across all 432 studies, recruiting or not: 84% stop at 75 or younger and 84% at 65; 22% take children; 98% are for women only and 0% for men only; 36% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dysmenorrhea studies take

Of 17 phase 3 interventional studies under Dysmenorrhea, half reached primary completion within 28 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 328 mo19–30 · 17 studies——
Interventional, no phase8 mo3–16 · 188 studies—8 mo4–16 · 178 studies
Observational23 mo4–47 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 432. Browse all 432 → or search them.